Go to deals
Healthcare

Alcidion (ASX:ALC) has completed a capital raise

Alcidion (ASX:ALC) has raised funds to continue its growth strategy.

Alcidion is transforming healthcare with smart, intuitive and complementary software products and services that create a unique offering in the global healthcare market. These solutions support interoperability, allow communication and task management, and deliver clinical decision support at the point of care to improve patient systems.

Oaklins’ team in Australia acted as lead manager in this transaction.

Talk to the deal team

Justin Lewis

Managing Director
Melbourne, Australia
Oaklins Henslow

Scott McInnes

Managing Director
Melbourne, Australia
Oaklins Henslow

Sebastian Bell

Director
Sydney, Australia
Oaklins Henslow

Related deals

MEDIK Hospital Design Group has been acquired by STERIS
Construction & Engineering Services | Healthcare

MEDIK Hospital Design Group has been acquired by STERIS

The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.

Learn more
Electro Optic Systems has acquired the UK interceptor business of MARSS
Aerospace, Defense & Security

Electro Optic Systems has acquired the UK interceptor business of MARSS

Electro Optic Systems Holdings Limited (ASX: EOS) has acquired the UK-based interceptor unmanned aerial system business of MARSS Group for US$6.4 million (€5.5 million). The interceptor is a reusable electric drone effector guided by imaging sensors and AI, which EOS will integrate into its counter-drone portfolio for defense and critical infrastructure customers. EOS plans further investment to complete development.

Learn more
bioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Healthcare

bioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG

Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.

Learn more